If Priced Similarly to Pradaxa, Surveyed MCOs Say They Will Place Apixaban in Tiers 1 or 2 in 60 Percent of Health Plans If It Shows Superior Stroke Prevention Efficacy and Lower Major Bleeding Rates Than Warfarin, According to a New Report from Decision Resources
BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, according to surveyed cardiologists in the United States, Bristol-Myers Squibb/Pfizer's apixaban would emerge as the patient-share leading new anticoagulant for stroke prevention in atrial fibrillation with a clinical profile of superior stroke prevention efficacy and lower rates of major bleeding relative to warfarin, as seen in the recent ARISTOTLE study. As a result, the use of Bayer/Janssen's Xarelto and Boehringer Ingelheim’s Pradaxa would be significantly impacted.
The new U.S. Physician & Payer Forum report entitled Pradaxa, Xarelto, and Apixaban for Atrial Fibrillation: How Have Phase III Data Informed Physician and Payer Perceptions of These New Anticoagulants? finds that there is a substantial unmet need for new, fixed-dose anticoagulants with efficacy profiles that are superior to warfarin. Although Pradaxa is superior to warfarin in terms of efficacy, its 150 milligram twice-daily dose has a similar level of major bleeding. With a profile of greater stroke prevention efficacy combined with lower rates of major bleeding compared to warfarin, on average, surveyed U.S. cardiologists estimate that almost 30 percent of their atrial fibrillation patients would be prescribed apixaban.
“This clinical scenario of apixaban, as recently demonstrated in the drug’s pivotal ARISTOTLE trial, stands to profoundly alter the competitive dynamics of the atrial fibrillation drug market as well as the fortunes of rival agents Xarelto and Pradaxa,” said Decision Resources Analyst Matthew Killeen, Ph.D. “At a price point similar to Pradaxa, surveyed pharmacy directors indicate that they would place apixaban in tiers 1 or 2 in 60 percent of managed care organization (MCO) plans if apixaban were to show superior stroke prevention efficacy and lower rates of major bleeding as compared to warfarin.”
According to surveyed MCO pharmacy directors, superior stroke prevention efficacy, mortality and major bleeding over warfarin are the most important achievements for new anticoagulants in terms of formulary inclusion. Forty-five percent of surveyed pharmacy directors rank superior stroke prevention efficacy relative to warfarin as the most persuasive attribute in deciding whether to include a new antithrombotic agent in their health plan’s formulary. One quarter of surveyed pharmacy directors point to lower rates of major bleeding relative to warfarin as the key driver for formulary inclusion of a novel antithrombotic agent and the same proportion also cite reduction in death rate over warfarin as a key driver for formulary inclusion.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
Christopher Comfort, 781-993-2597
KEYWORDS: United States North America Massachusetts
INDUSTRY KEYWORDS: Health Biotechnology Cardiology Pharmaceutical